By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
October 10, 2025 4:47 PM EDT
Medical Herald
Search
  • Health Conditions
    Health ConditionsShow More
    Reevaluating Hormone Therapy for Breast Cancer Survivors
    Breast Cancer
    New Study Links Circadian Protein to Alzheimer’s Treatment
    Alzheimer
    Biomea’s Icovamenib Drug Shows Potential for Diabetes Patients
    Diabetes
    New Insights into Tuberculosis and Macrophage Interactions
    Health Conditions
    New Study Finds Ways to Lower Peanut Allergy Risk in Kids
    Health Conditions
  • Wellness & Self-Care
    Wellness & Self-CareShow More
    Understanding the Complexity of Fear and Anxiety
    Mental Health
    Scarlett Johansson’s Skincare Line Discounts for October Prime Day
    Skin Care
    Transform Your Sleep with Beckham Hotel Collection Pillows
    Wellness & Self-Care
    Heart Health Tips: Best Exercises for Those Over 50
    Heart Health
    The Key Habit for Longevity After 50, According to Experts
    Longevity
  • Nutrition & Fitness
    Nutrition & FitnessShow More
    Discover the Benefits of a 15-Minute Pilates Core Workout
    Fitness
    Smucker’s Uncrustables Introduce Higher Protein Sandwich
    Diet & Nutrition
    Save $70 on Fitbit Versa 4 Smartwatch Deal
    Fitness Trends & Tech
    Top Early Prime Day Fitness Equipment Deals Unveiled
    Fitness Trends & Tech
    U.S. Beef Demand Surges, Imports Rise to Meet Protein Craze
    Diet & Nutrition
  • Innovation
    InnovationShow More
    Impact of Frozen Grants on Drug Development: A Deep Dive
    Innovation
    Telomir Pharmaceuticals Sees 39% Surge After Positive Study Results
    Innovation
    Direct Reduced Iron Market Set for Steady Growth Through 2034
    Innovation
    Nobel Prize in Medicine Awarded for Autoimmune Research Breakthroughs
    Innovation
    Global Clean Energy Growth Surpasses Demand for Fossil Fuels
    Innovation
  • News
    NewsShow More
    Nationwide Recall of Twin Marquis Noodles Due to Egg Risk
    News
    Idaho Families Face Health Care Crisis as Government Shutdown Looms
    News
    Novo Nordisk Makes Job Cuts at Major U.S. Plant
    News
    First Energy Distributes $750,000 to Food Banks in Pennsylvania
    News
    Jane Wilkens Celebrates 100 Years of Family and Resilience
    News
Font ResizerAa
Medical HeraldMedical Herald
  • Health Conditions
  • Wellness & Self-Care
  • Nutrition & Fitness
  • Innovation
  • News
Search
  • Health Conditions
  • Wellness & Self-Care
  • Nutrition & Fitness
  • Innovation
  • News
Follow US
Copyright © 2025, Medical Herald. All Rights Reserved.
Home » Innovation » Telomir Pharmaceuticals Sees 39% Surge After Positive Study Results

Telomir Pharmaceuticals Sees 39% Surge After Positive Study Results

By Samuel Lee
Published: October 10, 2025
Share

Telomir Pharmaceuticals Inc. (NASDAQ:TELO) experienced a significant boost in after-hours trading on Monday, with shares climbing 38.71% to reach $1.97. This surge followed the release of promising preclinical study results concerning its leading compound, Telomir-1.

Contents
  • Key Study Findings on DNA Methylation
  • Ongoing Development
  • Stock Performance Overview
  • Conclusion

The day’s trading began with a modest increase, as the stock edged up 1.43% during regular hours, closing at $1.42 based on data from Benzinga Pro.

Key Study Findings on DNA Methylation

In a filing with the SEC under Form 8-K, the Florida-based biotechnology company disclosed findings from research indicating that Telomir-1 demonstrated the ability to reverse abnormal deoxyribonucleic acid (DNA) methylation in aggressive prostate cancer models.

This reversal was significant as it restored the function of two essential tumor suppressor genes—MASPIN and RASSF1A—which are frequently silenced in cancer due to hypermethylation.

1. MASPIN’s Role: According to the company’s report, MASPIN plays several crucial roles in cancer defense mechanisms:

– It blocks tumor invasion and regulates cell migration and angiogenesis.
– It promotes apoptosis (programmed cell death).
– It enhances sensitivity to treatments.

Telomir-1 effectively reversed chemotherapy-induced DNA methylation, restoring MASPIN’s activity in living models (in vivo).

2. RASSF1A Functionality: RASSF1A is critical for:

– Regulating cell cycle control
– Promoting apoptosis
– Suppressing metastasis.

The findings indicated that Telomir-1 reduced RASSF1A methylation in a dose-dependent manner. Enhanced effects were observed particularly when Telomir-1 was administered alongside chemotherapy.

Ongoing Development

Telomir Pharmaceuticals has announced that it will continue its preclinical development alongside studies designed to enable Investigational New Drug (IND) applications, underscoring the ongoing commitment to advancing its pipeline.

Stock Performance Overview

Despite the recent uptick, TELO has struggled throughout the year, currently down 65.53% year-to-date. However, it has shown signs of recovery, posting a 15.45% gain in the past month. Over the last year, shares have fluctuated between $1.12 and $7.08, reflecting the volatility within the market.

The company currently holds a market capitalization of $45.84 million and has an average daily trading volume of 3.33 million shares. An analysis from Benzinga Edge Stock Rankings reveals a concerning negative price trend for TELO across all time frames, indicating potential challenges ahead.

Conclusion

As Telomir Pharmaceuticals continues to develop Telomir-1, the recent study results have sparked renewed interest in the stock. Investors and analysts will be closely watching how the company navigates its next steps in the challenging biotech landscape, particularly in regard to its ongoing preclinical studies. The potential impact on the treatment of aggressive prostate cancer could position Telomir-1 as a significant player in the field if future results align with these promising findings.Drugs & Medications

TAGGED:Telomir Pharmaceuticals
Share This Article
Facebook LinkedIn Email Copy Link
Leave a Comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

HOT NEWS

Nationwide Recall of Twin Marquis Noodles Due to Egg Risk

October 10, 2025

Idaho Families Face Health Care Crisis as Government Shutdown Looms

As enhanced health insurance tax credits near expiration, Idaho families brace for steep premium hikes…

October 10, 2025

Reevaluating Hormone Therapy for Breast Cancer Survivors

Emerging studies reveal hormone therapy could be safe for select breast cancer survivors, prompting a…

October 10, 2025

Novo Nordisk Makes Job Cuts at Major U.S. Plant

Novo Nordisk trims its U.S. workforce amid surging demand for diabetes and obesity drugs, reflecting…

October 10, 2025

YOU MAY ALSO LIKE

Drones Aim to Ensure Medication Access in Maryland Communities

A new drone program in Maryland is helping isolated communities like Smith Island receive medications faster, improving access and care.

October 1, 2025

Impact of Frozen Grants on Drug Development: A Deep Dive

Federal funding freezes under the Trump administration jeopardize university-led drug research behind lifesaving drugs like Ozempic, Keytruda, and Truvada.

October 10, 2025

Nobel Prize in Medicine Awarded for Autoimmune Research Breakthroughs

Three scientists win the 2023 Nobel Prize in Medicine for discoveries on regulatory T cells that protect the body from…

October 9, 2025

AI and Precision Mental Health: Transforming Care with Technology

AI is transforming mental health care through precision treatments, digital twins, and multi-modal diagnostics for more personalized, data-driven therapy.

October 1, 2025

Medical Herald is your trusted source for medical news, scientific research, health policy updates, and expert insights from around the world. 

Category

  • Health Conditions
  • Wellness & Self-Care
  • Nutrition & Fitness
  • Innovation
  • News
  • Privacy Policy
  • About Us
  • Contact

Follow US: 

  • Grow Big Agency Sites:
  • London Business Journal
Copyright © 2025, Medical Herald. All Rights Reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?